RAB7A

Across TCGA pan-cancer cohorts, RAB7A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB7A data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAB7A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB7A expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where RAB7A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.810	0.530	.001	32	view →
LUAD	OS	Median	III,IV	0.168	0.787	.014	8	view →
CCRCC	DFS	Median	All	0.634	0.850	.018	7	view →
GBM	DFS	Median	All	0.655	0.776	.026	5	view →
PDAC	DFS	Median	III,IV	0.493	0.934	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB7A–HNSC (DFS)

Open the HNSC breakdown →